News
PFE
27.19
+0.10%
0.03
Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study
TipRanks · 2h ago
Regeneron: Fairly Valued Now After A Stellar Upswing
Seeking Alpha · 5h ago
Wells Fargo Sticks to Its Hold Rating for Pfizer (PFE)
TipRanks · 8h ago
Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk
Dow Jones · 8h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Pfizer (PFE) and Medtronic (MDT)
TipRanks · 8h ago
Pfizer: Cheap For A Reason
Seeking Alpha · 10h ago
Pfizer Tariff Exemptions And US$70b Pledge Reshape Valuation Debate
Simply Wall St · 14h ago
Moderna: Pipeline Hope Won't Pay The Bills
Seeking Alpha · 23h ago
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE)
TipRanks · 1d ago
2 Healthcare Stocks That Are Too Cheap to Ignore
The Motley Fool · 1d ago
XLV, UNH, TMO, PFE: Large Outflows Detected at ETF
NASDAQ · 1d ago
3 Healthcare Stocks Paying the Highest Dividends of 2026
NASDAQ · 1d ago
BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm.
Barron‘s · 1d ago
BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture
Benzinga · 1d ago
BioNTech falls on outlook, departure of co-founders
Seeking Alpha · 1d ago
BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.
Barron‘s · 1d ago
Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
TipRanks · 1d ago
BioNTech sees FY26 revenue EUR 2B-EUR 2.3B
TipRanks · 1d ago
Pfizer (PFE) Valuation Check After New Tilrekimig Phase 2 Success And Pipeline Progress
Simply Wall St · 1d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.